8-K

                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549



                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported): November 11, 2002





                          QUINTILES TRANSNATIONAL CORP.
             (Exact name of registrant as specified in its charter)


     NORTH CAROLINA                000-23520                 56-1714315
    (State or other          (Commission File No.)         I.R.S. Employer
      jurisdiction                                      Identification Number
   of incorporation)


             4709 CREEKSTONE DRIVE, RIVERBIRCH BUILDING, SUITE 200,
                       DURHAM, NORTH CAROLINA 27703-8411
                    (Address of principal executive offices)



                                 (919) 998-2000
              (Registrant's telephone number, including area code)


                                       N/A
          (Former name or former address, if changed since last report)







ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS.*

         (c)      Exhibits

Exhibit Number    Description of Exhibit
- --------------    ----------------------

99.01             Press Release, dated November 11, 2002, of Quintiles
                  Transnational Corp.


ITEM 9.  REGULATION FD DISCLOSURE.*

            On November 11, 2002, Quintiles Transnational Corp. (the "Company")
issued a press release in which the Special Committee of its Board of Directors
announced that it had rejected the proposal by Pharma Services Company, an
entity wholly owned by Dennis B. Gillings, Ph.D., Chairman of the Board and
Founder of the Company, to acquire all outstanding shares of the Company's
common stock. A copy of the press release is attached hereto as Exhibit 99.01
and incorporated by reference herein.





* The information in this Current Report on Form 8-K, including the exhibit, is
furnished pursuant to Item 9 and shall not be deemed to be "filed" for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liability of that section. Furthermore, the information
in this Current Report on Form 8-K, including the exhibits, shall not be deemed
to be incorporated by reference into the filings of the Company under the
Securities Act of 1933, as amended.





                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                                   QUINTILES TRANSNATIONAL CORP.



                                                   By: /s/ James L. Bierman
                                                       ------------------------
Dated: November 12, 2002                               James L. Bierman
                                                       Chief Financial Officer










EXHIBIT INDEX


Exhibit Number      Description of Exhibit
- --------------      ----------------------------
99.01               Press Release, dated November 11, 2002, of Quintiles
                    Transnational Corp.

EX-99.1

                                                                   EXHIBIT 99.01

FOR IMMEDIATE RELEASE
CONTACT:
Pat Grebe, Media Relations
(media.info@quintiles.com)
Greg Connors, Investor Relations
(invest@quintiles.com)
919 998 2000

QUINTILES TRANSNATIONAL SPECIAL COMMITTEE REJECTS PROPOSAL BY PHARMA SERVICES
COMPANY TO ACQUIRE ALL OUTSTANDING SHARES

RESEARCH TRIANGLE PARK, N.C. - November 11, 2002 - The Special Committee of the
Quintiles Transnational Corp. (Nasdaq: QTRN) Board of Directors announced today
that it had rejected the proposal by Pharma Services Company to acquire all
outstanding shares of Quintiles common stock for $11.25 per share as inadequate
and not in the best interests of Quintiles and its shareholders. The conclusion
of the Special Committee was reached after careful consideration, including a
thorough review with its independent financial advisor, Morgan Stanley, and its
independent legal advisor, Willkie Farr & Gallagher. Pharma Services Company is
wholly owned by Dennis B. Gillings, Ph.D., Chairman of the Board and Founder of
Quintiles. Its non-binding proposal was announced on October 14.

The Special Committee also announced that together with Morgan Stanley it will
investigate strategic alternatives available to Quintiles for the purpose of
enhancing shareholder value, including the possibility of a sale of the company
and alternatives that would keep Quintiles independent and publicly owned. The
Special Committee has not made any determination as to whether a sale of the
company or any other alternative would best serve the interests of Quintiles and
its shareholders.

Quintiles Transnational helps improve healthcare worldwide by providing a broad
range of professional services, information and partnering solutions to the
pharmaceutical, biotechnology and healthcare industries. Headquartered near
Research Triangle Park, North Carolina, Quintiles is a member of the S&P 500 and
Fortune 1000. For more information visit Quintiles' Web site at
www.quintiles.com.

Information in this press release contains "forward-looking statements" about
Quintiles. These statements involve risks and uncertainties that could cause
actual results to differ materially, including without limitation, the
possibility that no transaction will be approved or completed, the possibility
that Quintiles might not prevail in pending litigation regarding the management
buyout proposal and other uncertainties arising in connection therewith.
Additional factors that could cause actual results to differ materially are
discussed in Quintiles' recent filings with the Securities and Exchange
Commission, including but not limited to its Annual Report on Form 10-K, its
Form 8-Ks and its other periodic reports, including Form 10-Qs.